Neurotransmitter imaging

Pediatric PET Imaging

Volumn , Issue , 2006, Pages 385-403

  Fischman, Alan J ^a   Badgaiyan, Rajendra D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889989484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-34641-4_21     Document Type: Chapter

References (98)

1. Jacobs AH, Li H, Winkeler A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging 2003;30:1051-1065.
2. Blankenberg FG. Molecular imaging: The latest generation of contrast agents and tissue characterization techniques. J Cell Biochem 2003;90: 443-453.
3. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol 2005;63:1-20.
4. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000; 20:423-451.
5. Alpert NM, Badgaiyan RD, Livini E, Fischman AJ. A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. NeuroImage 2003;19:1049-1060.
6. Badgaiyan RD, Alpert NM, Fischman AJ. Detection of striatal dopamine release during an implicit motor memory task. Annual meeting of the Society of Nuclear Medicine, Philadelphia, 2004.
7. Badgaiyan RD, Alpert NM, Fischman AJ. Detection of striatal dopamine released during an explicit motor memory task. Annual meeting of the Society of Nuclear Medicine, Toronto, 2005.
8. Badgaiyan RD, Alpert NM, Fischman AJ. Detection of striatal dopamine release during a motor planning task in human volunteers. Brain'03, XXIst International Symposium on Cerebral Blood Flow, Metabolism and Function (abstract 706). Calgarg, 2003.
9. Badgaiyan RD, Fischman AJ, Alpert NM. Striatal dopamine release during unrewarded motor task in human volunteers. NeuroReport 2003;14:1421-1424.
10. Badgaiyan RD, Fischman AJ, Alpert NM. Striatal dopamine release during unrewarded motor task in human volunteers. Neuroreport 2003;14:1421-1424.
11. Koepp MJ, Gunn RN, Lawrence AD, et al. Evidence for striatal dopamine release during a video game. Nature 1998;393:266-268.
12. Pappata S, Dehaene S, Poline JB, et al. In vivo detection of striatal dopamine release during reward: A PET study with ((11)C)raclopride and a single dynamic scan approach. NeuroImage 2002;16:1015-1027.
13. Morris ED, Alpert NM, Fischman AJ. Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies. J Cereb Blood Flow Metab 1996;16:841-853.
14. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2:303-312.
15. Maria Moresco R, Messa C, Lucignani G, et al. PET in psychopharmacology. Pharmacol Res 2001;44:151-159.
16. Wagner HNJ, Dannals RF, Frost JJ, et al. Imaging neuroreceptors in the human brain in health and disease. Radioisotopes 1985;34:103-107.
17. Wong DF, Gjedde A, Wagner HNJ. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:137-146.
18. Wong DF, Young D, Wilson PD, Meltzer CC, Gjedde A. Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: Theory, validation, and changes during normal aging. J Cereb Blood Flow Metab 1997;17:316-330.
19. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227.
20. Laruelle M, al-Tikriti MS, Zea-Ponce Y, et al. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with (123I)iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 1994;263:39-51.
21. Saelens JK, Simke JP, Neale SE, Weeks BJ, Selwyn M. Effects of haloperidol and d-amphetamine on in vivo 3H-spiroperiodol binding in the rat forebrain (1). Arch Int Pharmacodyn Ther 1980;246:98-107.
22. Chugani DC, Ackermann RF, Phelps ME. In vivo (3H)spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb Blood Flow Metab 1988;8:291-303.
23. Laruelle M, Huang Y. Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 2001;45:124-138.
24. Christian BT, Narayanan TK, Shi B, Mukherjee J. Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of ((18)F) fallypride in nonhuman primates. Synapse 2000;38:71-79.
25. dePaulis T. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. Curr Pharm Des 2003;9:673-696.
26. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18Ffallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002;46:170-188.
27. Mukherjee J, Christian BT, Narayanan TK, Shi B, Collins D. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in nonhuman primates using PET. Brain Res 2005;1032:77-84.
28. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7(suppl 1):S1-S5.
29. Wong DF, Wagner HNJ, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563.
30. Marzella PL, Hill C, Keks N, Singh B, Copolov D. The binding of both (3H)nemonapride and (3H)raclopride is increased in schizophrenia. Biol Psychiatry 1997;42:648-654.
31. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with (11C)raclopride. Arch Gen Psychiatry 1990;47:213-219.
32. Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: Implications for imaging studies in schizophrenia. Neuropsychopharmacology 2003;28:1703-1711.
33. Seeman P. Brain dopamine receptors in schizophrenia: PET problems. Arch Gen Psychiatry 1988;45(6):598-600.
34. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by (3H)raclopride: Implications for positron emission tomography of the human brain. Synapse 1989;3:96-97.
35. Xu ZC, Ling G, Sahr RN, Neal-Beliveau BS. Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion. Brain Res 2005;1038:163-170.
36. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371-384.
37. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94:2569-2574.
38. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-9240.
39. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-767.
40. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72.
41. Voruganti L, Slomka P, Zabel P, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 2001;25:642-650.
42. Fischman AJ. Role of (18F)-dopa-PET imaging in assessing movement disorders. Radiol Clin North Am 2005;43:93-106.
43. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic (18F)fluorodopa study. Arch Gen Psychiatry 2004;61:134-142.
44. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol 2005;204:355-360.
45. Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. Synapse 1998;29:128-141.
46. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
47. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423.
48. DiMaio S, Grizenko N, Joober R. Dopamine genes and attention-deficit hyperactivity disorder: A review. J Psychiatry Neurosci 2003;28:27-38.
49. Madras BK, Miller GM, Fischman AJ. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 2002;130:57-63.
50. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354(9196):2132-2133.
51. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density in the basal ganglia assessed with (123I)IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 2003;30:306-311.
52. Dresel S, Krause J, Krause KH, et al. Attention deficit hyperactivity disorder: binding of (99mTc)TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000;27:1518-1524.
53. Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003;34:77-80.
54. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl) 2003; 166:264-270.
55. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. Neurobiol Learn Mem 2002;78:610-624.
56. Daws LC, Callaghan PD, Moron JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 2002;290:1545-1550.
57. Kahlig KM, Binda F, Khoshbouei H, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 2005;102:3495-3500.
58. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414-9418.
59. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with (11C)WIN-35, 428. J Neurosci 1998;18:8417-8422.
60. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996;2: 699-703.
61. Parsey RV, Mann JJ. Applications of positron emission tomography in psychiatry. Semin Nucl Med 2003;33:129-135.
62. Merlet I, Ostrowsky K, Costes N, et al. 5-HT1Areceptor binding and intracerebral activity in temporal lobe epilepsy: An (18F)MPPF-PET study. Brain 2004;127:900-913.
63. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003;60: 749-756.
64. Juhasz C, Chugani DC, Muzik O, et al. Alpha-methyl-L-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology 2003;60:960-968.
65. Farde L, Ginovart N, Ito H, et al. PET-characterization of (carbonyl-11C)WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology (Berl) 1997;133:196-202.
66. Parsey RV, Mann JJ. Applications of positron emission tomography in psychiatry. Semin Nucl Med 2003;33:129-135.
67. Sihver W, Langstrom B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl 2000;176:27-33.
68. Nordberg A, Hartvig P, Lilja A, et al. Decreased uptake and binding of 11Cnicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect 1990;2:215-224.
69. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21-27.
70. Nordberg A, Amberla K, Shigeta M, et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 1998;12:228-237.
71. Yoshida T, Kuwabara Y, Ichiya Y, et al. Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-Nmethyl-4-piperidyl benzilate-comparison with cerebral blood flow and cerebral glucose metabolism. Ann Nucl Med 1998;12:35-42.
72. Maziere M, Hantraye P, Prenant C, Sastre J, Comar D. Synthesis of ethyl 8-fluoro-5, 6-dihydro-5-(11C)methyl-6-oxo-4H-imidazo (1, 5-a) (1, 4)benzodiazepine-3-carboxylate (RO 15.1788-11C): A specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 1984;35:973-976.
73. Hammers A. Flumazenil positron emission tomography and other ligands for functional imaging. Neuroimaging Clin North Am 2004;14:537-551.
74. Matheja P, Ludemann P, Kuwert T, et al. Disturbed benzodiazepine receptor function at the onset of temporal lobe epilepsy-lomanzenil-binding in de-novo TLE. J Neurol 2001;248:585-591.
75. Mitterhauser M, Wadsak W, Wabnegger L, et al. Biological evaluation of 2?-(18F)fluoroflumazenil ((18F)FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol 2004;31:291-295.
76. Heiss WD, Graf R, Fujita T, Ohta K, Bauer B, Lottgen J, Wienhard K. Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats. Stroke 1997;28:2045-2051; discussion 2051-2052.
77. Savic I, Pauli S, Thorell JO, Blomqvist G. In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy. J Neurol Neurosurg Psychiatry 1994;57:797-804.
78. Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis. An objective in vivo analysis. Brain 1996;119:1677-1687.
79. Debets RM, Sadzot B, van Isselt JW, et al. Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? J Neurol Neurosurg Psychiatry 1997;62:141-150.
80. Juhasz C, Chugani DC, Muzik O, et al. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001;56:1650-1658.
81. Bouvard S, Costes N, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazepine receptors in partial epilepsy: A (11C)flumazenil-PET study. Brain 2005;128:1330-1343.
82. Savic I, Svanborg E, Thorell JO. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: A positron emission tomography study. Epilepsia 1996;37:236-244.
83. Machulla HJ, Heinz A. Radioligands for brain imaging of the kappa-opioid system. J Nucl Med 2005;46:386-387.
84. Bencherif B, Wand GS, McCaul ME, et al. Mu-opioid receptor binding measured by (11C)carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 2004;55:255-262.
85. Cohen RM, Andreason PJ, Doudet DJ, Carson RE, Sunderland T. Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J Neurol Sci 1997;148:171-180.
86. Prevett MC, Cunningham VJ, Brooks DJ, Fish DR, Duncan JS. Opiate receptors in idiopathic generalised epilepsy measured with (11C)diprenorphine and positron emission tomography. Epilepsy Res 1994;19:71-77.
87. Bartenstein PA, Prevett MC, Duncan JS, Hajek M, Wieser HG. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res 1994;18:119-125.
88. McConathy J, Owens MJ, Kilts CD, et al. Synthesis and biological evaluation of (11C)talopram and (11C)talsupram: candidate PET ligands for the norepinephrine transporter. Nucl Med Biol 2004;31:705-718.
89. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 2001;6:663-666, 670.
90. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451-8458.
91. Morris ED, Fisher RE, Alpert NM, Rauch SL, Fischman AJ. In vivo imaging of neuromodulation using positron emission tomography: optimal ligand characteristics and task length for detection of activation. Hum Brain Map 1995;3:35-55.
92. Fisher RE, Morris ED, Alpert NM, Fischman AJ. In vivo imaging of neuromodulatory synaptic transmission using PET: A review of relevant neurophysiology. Hum Brain Map 1995;3:24-34.
93. Dewey SL, MacGregor RR, Brodie JD, et al. Mapping muscarinic receptors in human and baboon brain using (N-11C-methyl)-benztropine. Synapse 1990;5:213-223.
94. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by (3H)raclopride: Implications for positron emission tomography of the human brain. Synapse 1989;3:96-97.
95. Friston KJ, Malizia AL, Wilson S, Cunningham VJ, Jones T, Nutt DJ. Analysis of dynamic radioligand displacement or "activation" studies. J Cereb Blood Flow Metab 1997;17:80-93.
96. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6:279-287.
97. Mukherjee J, Yang ZY, Lew R, et al. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 1997; 27:1-13.
98. Chou YH, Halldin C, Farde L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study. Synapse 2000;38:138-143.